Jerrold S. Parker, Founding Partner of Parker Waichman LLP, Named to Plaintiffs' Steering Committee in Actos Bladder Cancer Lawsuit Litigation

Share Article

Jerrold S. Parker, Managing Partner with the National Law Firm of Parker Waichman LLP, has been named to the Plaintiffs' Steering Committee in the Actos (Pioglitazone) Products Liability Litigation (MDL 2299) Currently Underway in U.S. District Court for the Western District of Louisiana.

PW Logo
Lawsuits pending in the litigation allege that patients who ingested Actos for more than a year are at increased risks for developing bladder cancer.

Jerrold S. Parker, Founding Partner of Parker Waichman LLP, a national law firm, has been appointed to the Plaintiffs' Steering Committee in the Actos (Pioglitazone) Products Liability Litigation (MDL 2299) currently underway in U.S. District Court for the Western District of Louisiana. Mr. Parker's appointment was announced by the Honorable Rebecca F. Doherty in a notice posted on the Court's website on March 12, 2012. Lawsuits pending in the litigation allege that patients who ingested Actos for more than a year are at increased risks for developing bladder cancer. Plaintiffs further allege that Takeda Pharmaceuticals and other Defendants promoted Actos as a safe and effective treatment for Type II diabetes, even though they knew or should have known that taking Actos for longer than 12 months increased the risk of bladder cancer. [lawd.uscourts.gov/MDL2299/html/news.html]

Actos, known generically as pioglitazone, was launched in 1999 by Takeda Pharmaceuticals America Inc. and Eli Lilly and Co., as a treatment for Type II diabetes. Actos, now one of Takeda's top-selling drugs, had global sales last year of $4.8 billion and accounts for 27 percent of the company's revenue. [businessweek.com/news/2012-03-13/takeda-actos-judge-names-lead-attorneys-in-u-dot-s-dot-bladder-cancer-lawsuits]

On September 17, 2010, the U.S. Food & Drug Administration (FDA) announced it had begun an Actos safety review after preliminary data from a study conducted by Kaiser Permanente demonstrated that the risk of bladder cancer increases with increasing dose and duration of Actos use, reaching statistical significance after 24 months. On June 15, 2011, the FDA issued another safety communication stating that use of Actos for more than one year may be associated with an increased risk of bladder cancer. When compared to persons never treated with Actos, taking the drug for more than 12 months was associated with a 40 percent increase in the risk of developing bladder cancer, the agency said. The FDA mandated that new information about this risk be added to the "Warnings and Precautions" section of the Actos label. [fda.gov/Drugs/DrugSafety/ucm259150.htm]

In the March 12 notice, Judge Doherty also appointed Richard Arsenault and Paul Pennock as Plaintiffs' Co-Lead Counsel in the litigation. Patrick Morrow was named Plaintiffs’ Liaison Counsel. Other attorneys appointed to the PSC are:

Chris Seeger
Jane Conroy
Dianne Nast
Mark Lanier
Neil Overholtz
Andy Birchfield
Vance Andrus
Steve Murray
James Singleton
Nick Drakulich
Troy Rafferty

Parker Waichman LLP continues to offer free legal consultations to victims of Actos. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting the firm's Actos injury page at http://www.yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

For more information regarding Actos bladder cancer lawsuits and Parker Waichman LLP, please visit http://www.yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Herb Waichman, Partner
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Herb Waichman, Partner
Parker Waichman LLP
(800) 529-4636
Email >
Visit website